Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non–small-cell lung cancer
M Fukuoka, S Yano, G Giaccone, T Tamura… - Journal of clinical …, 2003 - ascopubs.org
Purpose: To evaluate the efficacy and tolerability of two doses of gefitinib (Iressa [ZD1839];
AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase …
AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase …
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non–small-cell lung cancer: a meta-analysis of 13 randomized trials
F Petrelli, K Borgonovo, M Cabiddu, S Barni - Clinical lung cancer, 2012 - Elsevier
Advanced non–small-cell lung cancer (NSCLC) harboring activating mutations of epidermal
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …
growth factor receptor (EGFR) are particularly sensitive to tyrosine kinase inhibitors (TKIs) …
[HTML][HTML] Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
I Sullivan, D Planchard - Frontiers in medicine, 2017 - frontiersin.org
Tyrosine kinase inhibitors (TKIs) against the human epidermal growth factor receptor
(EGFR) are now standard treatment in the clinic for patients with advanced EGFR mutant …
(EGFR) are now standard treatment in the clinic for patients with advanced EGFR mutant …
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib …
Background Optimum management strategies for patients with advanced non-small-cell
lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase inhibitors are …
lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase inhibitors are …
Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy
BC Liao, CC Lin, JH Lee, JCH Yang - Lung Cancer, 2017 - Elsevier
The first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs),
gefitinib and erlotinib, and the second-generation EGFR-TKI, afatinib, have all been …
gefitinib and erlotinib, and the second-generation EGFR-TKI, afatinib, have all been …
[HTML][HTML] Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
IF Emery, C Battelli, PL Auclair, K Carrier, DM Hayes - BMC cancer, 2009 - Springer
Abstract Background In Non-small cell lung cancer (NSCLC), an overactive epidermal
growth factor receptor (EGFR) pathway is a component of the malignant phenotype. Two …
growth factor receptor (EGFR) pathway is a component of the malignant phenotype. Two …
Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
M Tiseo, M Bartolotti, F Gelsomino… - … design, development and …, 2010 - Taylor & Francis
Most patients with non-small-cell lung cancer (NSCLC) present with advanced disease and
their long-term prognosis remains poor. Epidermal growth factor receptor (EGFR)-targeted …
their long-term prognosis remains poor. Epidermal growth factor receptor (EGFR)-targeted …
[HTML][HTML] Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
L Paz-Ares, EH Tan, K O'Byrne, L Zhang, V Hirsh… - Annals of …, 2017 - Elsevier
ABSTRACT Background In LUX-Lung 7, the irreversible ErbB family blocker, afatinib,
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
significantly improved progression-free survival (PFS), time-to-treatment failure (TTF) and …
Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer—data from a randomized Phase III study …
E Miyauchi, A Inoue, K Kobayashi… - Japanese Journal of …, 2015 - academic.oup.com
Objective Epidermal growth factor receptor tyrosine kinase inhibitors are effective as first-line
therapy for advanced non-small cell lung cancer patients harboring epidermal growth factor …
therapy for advanced non-small cell lung cancer patients harboring epidermal growth factor …
[HTML][HTML] Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu, C Wang… - Annals of …, 2015 - Elsevier
Background The OPTIMAL study was the first study to compare efficacy and tolerability of the
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …
epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) erlotinib, versus …